Comparison
Methylene Blue vs Sermorelin
Side-by-side of Methylene Blue and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Methylene Blue
Methylene blue as a nootropic: low-dose cognitive enhancement, mitochondrial electron cycling, brain oxygen uptake, SSRI interaction risk, typical 0.5 to 4 mg.
Sermorelin
Sermorelin peptide therapy uses a 29-amino-acid GHRH analog to raise endogenous GH. Dosing, half-life, sermorelin vs ipamorelin, and safety.
Effects at a glance
Methylene Blue
- •FDA approved for methemoglobinemia and ifosfamide-induced encephalopathy
- •Mitochondrial electron-transport support at low doses (0.5 to 4 mg/kg) via cytochrome c shuttle
- •Potent MAO-A inhibitor; serotonin syndrome risk with SSRIs, SNRIs, MAOIs, fentanyl, tramadol, St John's wort
- •Causes harmless blue-green urine and sweat coloration; useful adherence marker
- •G6PD deficiency is an absolute contraindication; can trigger massive hemolysis
- •Cognitive-enhancement evidence is preliminary, mostly preclinical and small fMRI trials
Sermorelin
- •Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
- •Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
- •Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
- •Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
- •Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
- •Banned by WADA under S2 (peptide hormones, growth factors)
Side-by-side
| Attribute | Methylene Blue | Sermorelin |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Methylthioninium chloride, Provayblue, tetramethylthionine chloride | Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2 |
| Half-life (hr) ↗ | 5.5 | 0.25 |
| Typical dose (mg) ↗ | 70 | 0.3 |
| Dosing frequency | 1 to 3 times daily for cognitive use; single IV dose for methemoglobinemia | 1-2x daily |
| Routes | oral, intravenous | subcutaneous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 1.5 | 0.5 |
| Molecular weight | 319.85 | 3357.88 |
| Molecular formula | C16H18ClN3S | C149H246N44O42S |
| Mechanism | Mitochondrial electron carrier at low doses (cytochrome c shuttle to complex IV) and methemoglobin reductase substrate at higher doses; potent MAO-A inhibitor across the dose range. | Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop. |
| Legal status | Prescription (injectable, FDA approved); supplement form (oral) widely available; not scheduled | FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | Not scheduled in the US | Rx only via compounding (no controlled-substance schedule) |
| Pregnancy | Contraindicated | Category C (historical labeling); not recommended in pregnancy |
| CAS | 61-73-4 | 86168-78-7 |
| PubChem CID | 6099 | 16129617 |
| Wikidata | Q409021 | Q416620 |
Safety profile
Methylene Blue
Common side effects
- blue-green urine and sweat
- skin and oral mucosa staining
- GI upset
- headache
- dizziness
Contraindications
- G6PD deficiency
- pregnancy
- concurrent serotonergic medication
- severe renal impairment
- infants under 6 months
Interactions
- SSRIs and SNRIs: serotonin syndrome, potentially fatal(major)
- MAOIs: additive MAO inhibition, serotonin syndrome risk(major)
- fentanyl, tramadol, meperidine: serotonin syndrome risk(major)
- dextromethorphan: serotonin syndrome risk(major)
- St John's wort: serotonin syndrome risk(major)
- lithium: additive serotonergic risk(major)
Sermorelin
Common side effects
- injection-site pain or irritation
- transient flushing
- headache
- vivid dreams (pre-bed dosing)
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- diabetic retinopathy (theoretical)
- untreated hypothyroidism
Interactions
- ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
- CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
- levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)
Which Should You Take?
Methylene Blue comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Sermorelin is the right call when one of the conditionals below applies.
- → If your priority is focus or working memory, pick Methylene Blue.
- → If your priority is mitochondrial function, pick Methylene Blue.
- → If your priority is growth-hormone axis, pick Sermorelin.
- → If your priority is healthspan extension, pick Sermorelin.
Edge case: If you cannot self-administer injections, Methylene Blue is the only oral option in this pair.
Default choice: Methylene Blue. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Sermorelin only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Methylene Blue and Sermorelin?
Methylene Blue and Sermorelin differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Methylene Blue or Sermorelin?
Methylene Blue half-life is 5.5 hours; Sermorelin half-life is 0.25 hours.
Can you stack Methylene Blue with Sermorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper